Caris Life Sciences, Inc. (CAI) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 5 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for CAI is $31.33, representing a +55.2% upside from the current price of $20.19. Price targets range from a low of $26.00 to a high of $38.00.
